Method for cytoflavin electric accumulation in treating vascular and dystrophic retinal and visual nerve diseases
SUBSTANCE: invention refers to medicine, namely ophthalmology and physiotherapy, and may be used for treating vascular and dystrophic retinal and visual nerve diseases. That is ensured by the intravenous drop-by-drop infusion of the 2/3 amount of the medical solution made of cytoflavin 10 ml and 0.9% sodium chloride 200 ml. It is followed by 15-minite transverse halvanisation in the Potok-1 apparatus at current force making 0.5 mA. For this purpose 2 oval anode electrodes through a pad impregnated in distilled water are placed on skin of closed eyelids of both eyes and connected by a Y-wire with the anode of the apparatus. The third cathode electrode is placed transversally in relation to the two first anode electrodes on the area of upper cervical spines S2-S4 and connected with the cathode of the apparatus. The therapeutic course makes 10 daily procedures.
EFFECT: method provides high clinical effectiveness ensured by high functional effectiveness of cytoflavin electric accumulation in eye tissue with improving visual acuity by 0,15-0,3, prolonged action of the ensured therapeutic effect up to 5-6 months, eliminated risk of damaging an external eyeball capsule.
1 tbl, 2 ex
The invention relates to medicine, in particular to ophthalmology, physiotherapy, and can be used in the treatment of pathology visually-nervous apparatus of the eye.
The main method of treatment of vascular and degenerative diseases of the retina and optic nerve is a complex system and local pharmacotherapy, including, typically, a set of multiple drugs of different pharmacological groups: improves capillary perfusion of the nerve tissue, the offsets of energy metabolism, antihypoxants and antioxidants (Krasnogorsk). Abstract of "integrated System of treatment of degenerative diseases of the retina", Krasnoyarsk, 2008).
However, any injection method of administration of drugs, systemic, local, medicines, first of all, go into the General bloodstream, which bind plasma proteins and erythrocytes. Penetration into the tissue of the eye formed of high-molecular compounds largely prevents gematologicheskii barrier (y) and, accordingly, the treatment effect is clearly insufficient. In addition, a daily serial invasive introduction of at least 3-4 drugs: intravenous, intramuscular periocular causes the patient for a long psycho-emotional stress, which in turn forms the t high risk of adverse reactions and complications, for example, increased blood pressure, cardiovascular decompensation, exacerbation of chronic diseases. In addition, local periocular introduction of medicines associated in the injection zone to the danger of penetrating injuries of the outer capsule of the eye, representing a real threat of vision loss.
In recent years, to reduce the emotional burden on the patient's body and optimization of therapeutic possibilities tactics of treatment of vascular and degenerative diseases of any localization of practical interest-official multicomponent pharmacological solutions with polyfunctional orientation, containing from 2 to 4 compatible drugs that showed its electoral therapeutic efficacy in their stand-alone application, such as milgamma, Mexidol, cytoflavin. However, due to the presence of GOB for injectable way of introducing the multicomponent dosage solutions also not achieved therapeutic concentration of the ingredients in eye tissues necessary to restore and maintain the viability of the neurons of the retina and optic nerve.
With the aim of increasing the permeability of the GOB for drugs ophthalmologists widely used methods of pharmacophores - introduction Lakers the governmental funds using various physical factors and first of all, DC.
In ophthalmology use different methods of electrophoresis: Bourguignon through closed eyelids, or vannochkovogo electrophoresis on Cantona with open eye (Intein, Aguave "Physical therapy of eye diseases. Simferopol. Tavria. 1998, S. 21-22).
However, these methods are intended for the treatment of diseases, mainly of the anterior eye and are ineffective in the pathology of the retina and optic nerve.
The analog prototype of the invention is a method endonasal electrophoresis on Aphrodence - Iscussio - "occipital" method (Intein, Aguave "Physical therapy of eye diseases. Simferopol. Tavria. 1998, S. 9-11).
While cotton or gauze pads moistened with a solution of a medicinal substance, such as cytoflavin injected into both nasal progress to a depth of 1-2 cm at the ends of Turunc placed on the oilcloth 2×5 cm, located on the skin above the upper lip. On the free ends of the pads impose electrode and connected to one of the poles. The second electrode is placed in the neck and connected with the other pole.
The disadvantages of the method on the prototype:
- inadequate therapeutic efficacy as a medicinal substance comes first in the blood, and then only in the tissue of the retina, optic nerve, which enters only 2-5% (Vgenerally. "ELEH tritherapy". Moscow. "Medicine". 1987, S. 39) from the total amount of drug used in the procedure, a large portion is deposited in other organs and systems;
- inactivation of components of the medicinal solution products of electrolysis.
The objective is to propose a method of increasing the effectiveness of medical rehabilitation of patients with vascular and degenerative diseases of the retina and optic nerve.
The technical result - improving the efficiency of pathogenetic therapy in patients with vascular and degenerative diseases of the retina and optic nerve by electromodulation in the nervous tissue of the eye multicomponent drugs. For example, the composition of the multicomponent dosage solution - cytoflavin - includes: inosine, nicotinamide, Riboflavin - mononucleotide, succinic acid, the combination of these ingredients improves capillary perfusion and processes of oxygen utilization by the tissues, stimulates respiration and energy formation in the cells, the activity of antioxidant enzymes (VFS. Cytoflavin in intensive care. St. Petersburg, 2005).
The technical result is achieved by the fact that after the intravenous drip infusion 2/3 the volume of drug solution made from 10 ml of cytoflavin and 200 ml of 0.9% solution of sodium chloride, conduct Popper is know galvanizing apparatus "Thread-1". 2 electrode - anode oval shape of the eye through a pad moistened with distilled water, placed on the skin closed eyelids of both eyes and connect the forked wire - anode of the device, thus take into account the negative polarity of all components of cytoflavin medicinal components. 3rd electrode-cathode include a transversely with respect to the first two in the region of the upper cervical vertebrae (S2-S4) and is connected to a cathode. Current is 0.5 mA, duration of exposure 15 minutes, in the course of treatment prescribed 10 procedures carried out daily.
The advantage of the proposed method:
- high functional efficiency cytoflavin-electromodulation in patients with vascular and degenerative diseases of the retina and optic nerve with improvement of visual acuity in the 0.15-0.3;
the prolongation of the duration of the achieved therapeutic effect of up to 5 - 6 months due to electromodulation medicinal substances, as directed movement of negative ions all components of cytoflavin in the direction of the anode electrodes fixed in the field of both eyes, increases the excretion of the drug from the General flow, and it electromodulated in the eye tissues;
- there is no need for daily repetition, invasive procedures for the introduction of farmakologicheskaya, included in the standard treatment regimen;
- eliminates inactivation of drugs included in cytoflavin, products of electrolysis, as a medicinal substance is injected intravenously, and electrophoretic not;
- during the procedure, there is no risk of damage to the outer capsule of the eyeball, so as a way of introducing non-invasive.
The results of the application of cytoflavin-electromodulation in the treatment of vascular and degenerative diseases of the retina and optic nerve are shown in table 1.
Analysis of the obtained data has shown that the application of cytoflavin-electromodulation visual acuity after treatment has increased against the source of almost 1.6 times, while at endonasal cytoflavin-electrophoresis only 1.3 times; duration of therapeutic effect, respectively, increased by 2-3 months.
Example 1. Patient S., 59 years old. Clinical diagnosis: chronic ischemic neuroarthropathy both eyes. From the anamnesis: sick for 1.5 years, during this time twice received outpatient treatment: intravenous antioxidant solcoseryl in/muscle to improve intraocular capillary perfusion piracetam, periocular - Cortexin. Visual acuity of the right eye at the beginning of the disease was equal to 0.4, the left - 0,3 after courses of pharmacotherapy increased the ü to 0.5 in both eyes, however, after 2-3 months to return to baseline. To improve the efficiency of medical rehabilitation the patient in the physiotherapy Department was appointed cytoflavin-electromodulated: after intravenous drip infusion 2/3 the volume of drug solution made from 10 ml of cytoflavin and 200 ml of 0.9% solution of sodium chloride, were cross galvanization: 2 electrode - anode connected to the apparatus "Thread-1", was placed on the skin closed eyelids, 3rd electrode - cathode disposed transversely in the region of the upper cervical vertebrae S2-S4. After 10 treatments, the visual acuity of the right eye improved to 0.6, the left - to 0.5. The achieved therapeutic effect was maintained during the 6 months of observation.
Example 2. Patient K. 67 entered on the treatment of progressive exudative age-related macular degeneration in both eyes. Visual acuity at admission of the right eye of 0.4, the left eye is 0.5. Assigned cytoflavin-electromodulated. After 10 treatments, the visual acuity was: right eye 0,6, left - to 0.7. The achieved therapeutic effect lasted 5 months.
|Nosological form||n eyes||Cytoflavin-electroc the while accumulation||n eyes||Endonasal cytoflavin electrophoresis|
|Visual acuity||Length. the achieved effect||Visual acuity||Length. the achieved effect|
|ex.||After the treatment||ex.||After the treatment|
|Age-related macular degeneration||12||0,2-0,5||0,4-0,7||5-6 months||8||0,2-0,5||0,3-0,5||2-3 months|
|Chronic ischemic neuroarthropathy||10||01-0,3||0,3-0,6||6 months||9||0,25-0,5||0,3-0,5||3-4 months|
|Optic nerve atrophy||9||0,15-0,4||0,3-0,5||5-6 months||11||0,1-0,5||0,2-0,4||3 months|
The way cytoflavin-electromodulation in the treatment of vascular and degenerative diseases of the retina and optic nerve, comprising the electrophoretic introduction of cytoflavin, characterized in that after the intravenous drip infusion 2/3 the volume of drug solution made from 10 ml of cytoflavin and 200 ml of 0.9% solution of sodium chloride, conduct cross-galvanizing apparatus "Thread-1", 2 electrode - anode oval through the pad moistened with distilled water, placed on the skin closed eyelids of both eyes, then connect the electrodes - the anode bifurcated wire from the anode of the device, while taking into account the negative polarity of all components of cytoflavin medicinal components, 3rd electrode - cathode include a transversely with respect to the two first electrodes - the anode in the region of the upper cervical vertebrae S2-S4 and is connected to a cathode of the device, and the current is 0.5 mA, duration of exposure 15 min, in the course of treatment prescribed 10 procedures carried out daily.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relate to field of medicine, in particular, to ophthalmology. Method of stabilisation of eye composition, which includes oxidatively unstable pharmaceutical ingredient is ensured by addition of efficient quantity of stabilising substance, where stabilising substance is selected from group, which consists of silicon dioxide, N,N,N',N',N",N"-hexa(2-pyridyl)-1,3,5- tris(aminomethyl)benzene, diethylenetriaminepentaacetic acid and salts of diethylenetriaminepentaacetic acid. Eye composition has pH from approximately 6.6 to approximately 7.2.
EFFECT: group of inventions ensures efficiency and stability of eye composition at higher temperatures.
32 cl, 2 tbl, 3 dwg, 3 ex
SUBSTANCE: there are offered: there are offered as follows: a prophylactic or therapeutic drug applicable for age-related macular degeneration containing 2-phenyl-1,2 benzisoselenazol-3(2H)-one (ebselen) or its salt as an active ingredient, using it for preparing the prophylactic or therapeutic drug for the same application, related methods for prevention and therapy of age-related macular degeneration (versions). What is shown is an excellent inhibitory action of 2-phenyl-1,2 benzisoselenazol-3(2H)-one or its salt on neovascularisation in the choroid; what is also shown is protective action with respect to the damage of retinal pigment epithelial cells.
EFFECT: compound is applicable as the prophylactic or therapeutic drug for age-related macular degeneration.
8 cl, 3 tbl, 4 ex
SUBSTANCE: invention refers to pharmacology and represents a pharmaceutical composition for integrated treatment of ocular surface diseases in the patients suffering primary open-angle glaucoma, on the basis of phospholipids and sulphated glycosaminoglycans, differing by the fact that composition represents a liposomal emulsion formed by phospholipids in the form of liposomes, of average particle size 0.05-0.22 mcm, and sulphated glycosaminoglycans with sulphated glycosaminoglycans presented by keratan sulphate sodium salt and chondroitin sulphate sodium salt with the ingredients of the composition taken in certain proportions, wt %.
EFFECT: invention provides preventing lachrymal production from decreasing, reducing tear evaporation, as well as avoiding pathological changes in conjunctival and corneal epithelial cells.
SUBSTANCE: group of inventions refers to medicine, particularly to ophthalmology. An oil-in-water emulsion and a method for preparing it for ophthalmic application is characterised by at least one prostaglandin as an active agent, and a surface-active ingredient containing a combination of at least two non-ionic surfactants.
EFFECT: group of inventions provides treating glaucoma and is characterised by high chemical stability of the prostaglandin active agent that enables long-term storage of the emulsion at room temperature.
30 cl, 7 tbl, 11 ex
SUBSTANCE: invention relates to medicine, namely to physiotherapy in system of rehabilitation of patients with cataract. 1% solution of placenta hydrolysate is instilled in dose two drops in each nasal passage, and then physiotherapeutic influence by red laser irradiation with wave length 0.63 mcm with density of flow with power 5 mWt/cm2 is performed in continuous mode through nozzle into each nasal passage for 30 sec. Time of influence is increased after two procedures by 30 sec, bringing to 2 minutes into each nasal passage. Course includes 10 procedures daily, courses are repeated twice after 1 month.
EFFECT: method makes it possible to obtain long-term stabilisation in prepressing of cataract and prevent its maturation, improve trophism of both peripheral and central part of visual analyser, increasing visual acuity to physiological level, prevent dystrophic changes of eye structures.
3 tbl, 2 ex
SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and is intended for treatment of endophthalmitis. Method includes intravenous introduction of antibiotic of broad spectrum of action in single dose, for example, gentamicin. When maximal level of antibiotic concentration in blood is reached, autoserum is obtained. Vitrectomy is performed to patient. Operation is carried out with application of ozonised physiological solution for irrigation twice during 10 minutes. Then, eye cavity is washed with physiological solution during 2-3 minutes. Operation is finished by introduction into eye cavity of obtained autoserum until cavity volume is restored.
EFFECT: method ensures complete suppression of infectious process in eye cavity with preservation of eye as organ, with prospective of preservation of visual function as a result of reduction of toxic effect of antibiotic on retina.
SUBSTANCE: present invention refers to implanted ophthalmic devices for prolonged drug release in an eye, as well as to a method for making and using such devices. One version of the present invention refers to the device comprising: (a) a main portion accommodating a matrix consisting of prostaglandin and silicone; (b) a parylene coating on an external surface of the main portion; (c) one or more pores arranged on the end of the body which is closest to an anterior side of the eye wherein said pore extends from the external surface of the parylene coating to a surface of an upper portion of the body.
EFFECT: developing the implanted ophthalmic device for prolonged drug release in the eye.
23 cl, 3 ex, 8 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely otorhinolaryngology and may be used for treating internal ear disorders. That is ensured by using a 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt. Said derivative is introduced according to the titration schedule which involves increasing a dose of neramexane and gradually increasing a dose by 25 mg or 12.5 mg every week over a period of four to five weeks to achieve an effective daily dose of 50 to 75 mg. What is also presented is using the 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt, and a method of treating internal ear disorders in an individual in need thereof.
EFFECT: group of inventions enables the fast and safe achievement of the effective dose of neramexane with side effects herewith minimised.
14 cl, 9 dwg, 10 tbl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly ophthalmology, namely eye drops for dry eye syndrome with the formulation containing a lachrymal substitute and a corticosteroid: dexamethasone or betamethasone. The eye drops contain the following ingredients (wt %): dexamethasone phosphate or betamethasone phosphate - 0.000001-1.0; hydroxypropyl cellulose - 0.01-5.0; histidine hydrochloride monohydrate 0.01-0.025; boric acid 0.01-0.08; sodium tetraborate 0.0001-0.02; macrogol 400 - 0.001-0.1; disoudium edetate 0.001-0.05; potassium chloride - 0.001-0.008; sodium chloride 0.001-0.016 and the rest - purified water.
EFFECT: invention provides avoiding external eye irritation.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to application of an antisecretory factor, such as an antisecretory protein (AF), its homologue, and/or a fragment possessing antisecretory activity wherein the specified protein (AG) is related with an amino acid sequence presented in SEQ ID NO:6 and/or wherein the specified fragment contains the amino acid sequence presented in SEQ ID NO:4 for preparing a pharmaceutical composition applicable in treatment or prevention of intraocular pressure increase. Also, the invention concerns a peptide presented in SEQ ID NO:4, possessing antisecretory activity for prevention or treatment of intraocular pressure increase.
EFFECT: group of inventions provides the new therapeutic approach to treatment and/or prevention of such condition reducing the intraocular pressure to an acceptable level, optionally 21 mm Hg or less.
20 cl, 17 ex
SUBSTANCE: invention relates to medicine, namely to physiotherapy, gastroenterology. Method includes introduction of diet No5, internal intake of mineral water with the following carrying out transverse galvanisation of epigastrium area, general coniferous baths and impact with physical factor. As physical factor used is electromagnetic radiation of extremely high frequency (EHF). Impact is performed by broad-band noise emitter with frequency 40-63 GHz. Impact is performed on 3 and 4 projection zones in area of the right hypochondrium and on the area of sternum. Impact is performed daily, 10 minutes on each zone. Course includes 10-12 procedures.
EFFECT: method improves physical-chemical properties of bile, contributes to bile secretion due to normalising action on motor and secretory function of gastrointestinal tract, improves blood circulation and liver regeneration, increases non-specific resistance and adaptive possibilities of organism, normalises psycho-emotional status.
2 ex, 2 tbl, 1 dwg
SUBSTANCE: invention is referred to the field of medicine, namely to pediatrics and physical therapy. The method includes the exposure to silt sulphide dirt of Saki lake and constant continuous current. The dirt used in the process is placed in hydrophilic fabric bags-pads. The pads that are 3-5 cm thick, sized 10x16 cm, with the temperature 5-10°C, are placed on lateral and medial surface of operated knee joint. 2 electrodes sized 180 x 120 mm are placed on them. They are fixed with elastic bandages. Then constant continuous current is sent to the electrodes from “Potok-1” apparatus. With current power 0.02-0.08 mA the exposure time is 8-10-15 minutes. The procedures are performed daily. The course includes 8-10 procedures.
EFFECT: method provides for increased effectiveness of treatment, decreased pain syndrome, increased lymph flow speed, normalizes the parameters of venous flow, provides anti-edema and anti-inflammatory action, improves nutrition and regeneration of tissues, decreases hardening and fibrosis of tissues, shortens the terms of treatment and rehabilitation.
1 dwg, 2 ex, 5 dwg
SUBSTANCE: invention relates to field of medicine, namely to gynecology, and can be used in treatment of patients with climacteric syndrome of various severity degree. Method includes daily carrying out transcranial electric stimulation (TES) of brain protective mechanisms with constant current with intensity 1.5-2.5 mA, duration 20-30 minutes and introduction of medication "Sagenit". After carrying out each third TES session electric encephalogram is registered. If α-rhythm amplitude decreases lower than 30 mcV, TES sessions are not resumed. Treatment is continued by introduction of medication "Femoston 1/10" daily in dose 1 tablet per day during 2-3 weeks until amplitude of α-rhythm is restored above 30 mcV, with further introduction of medication "Sagenit" in dose 1 tablet per day during 2-3 months. If reduction of α-rhythm amplitude does not take place, 9-15 sessions of TES are carried out with the following introduction of medication "Sagenit" daily in dose 1 tablet per day during 20-30 days.
EFFECT: method makes it possible to increase degree of patients' adaptation taking into account individual peculiarities of organism, reduce probability of development of negative side effects in process of climacteric syndrome treatment.
SUBSTANCE: invention relates to medicine, namely to endocrinology, reflexology. Method includes selection of corporal biologically active points (BAP) of general health-improving action, auricular points and points, located in area of thyroid gland, estimation of electric conductivity of selected points and impact on BAPs. Preliminarily, by Nakatani method determined is functional state of classical acupuncture meridians GB, SP and BL. In case of GB meridian hyperfunction conclusion about hyperfunction of thyroid gland is made. In case of hypofunction of GB meridian conclusion about hypofunction of thyroid gland is made. Degree of hypofunction of SP and BL meridians is used to conclude about autoimmune process activity. In case of GB meridian hyperfunction and any degree of hypofunction of SP and BL meridians or hypofunction of GB meridian and expressed hypofunction of SP and BL meridians, poinbts of collar zone are added to selected for impact BAPs and sedative impact is performed on selected points. As points of general health-improving action selected are points TE5, LI10, ST36, GB34, segmental - SI15, SI16, GB12, GB20, symptomatic remote - GB39, BL40, BL60, points of collar zone - BL11, LI15, GB21, TE 17, and as auricular points - AT22, AT25, AT45, AT51, AT55. In case of meridian GB hypofunction and moderate hypofunction of SP and BL meridians, to selected for impact BAPs added are symptomatic local points in area of thyroid gland, and tonic impact is performed on selected points. As points of general health-improving action selected are points TE5, LI4, LI10, LIU, ST36, GB34, segmental - SI15, SI16, GB20, symptomatic remote - GB39, GB41, symptomatic local points in area of thyroid gland - ST12, KI27, SI17, auricular - AT22, AT45, AT51, AT55. Sedative impact on BAPs is performed by constant electric current of negative polarity. Tonic impact is performed by alternating electric current. Required number of procedures is determined taking into account degree of hypofunction of SP and BL meridians before beginning treatment course.
EFFECT: method increases efficiency of treatment of autoimmune diseases of thyroid gland due to preliminary estimation of its functional state and selection of BAPs and type of electropunctural impact taking into account determined state.
3 cl, 3 ex
SUBSTANCE: standard treatment regimen additionally includes gliatilin which is injected intramuscularly 2 ml daily in the therapeutic course 10 injections, and combined with transcranial micropolarisation. Transcranial micropolarisation is performed every second day at exposition 20 minutes on the first session with exposure time to be increased by 5 minutes on each following session; the therapeutic course is 5 procedures. Electrodes are applied on a frontoanterior area (an anode), on a mastoid process (cathode), on an occipital region (anode) of a hemisphere with the same name with involving thereafter an opposite hemisphere in the end of treatment.
EFFECT: improved values of a visual memory, a audio-voice memory, attention, thought processes, emotional sphere that allows reducing considerably hospitalisation length and providing higher clinical effectiveness.
10 tbl, 1 ex
SUBSTANCE: invention refers to the field of medicine, namely to ophthalmology, oncology. Electrochemical lysis of tumour is carried out. Two platinum electrodes are used for this purpose. One electrode is arranged in the form of net with round hole in centre. Electrode shape matches projection of tumour base onto sclera. At the same time surface of net coated with insulation material is implanted into sclera. The second electrode is needle type. It is inserted into tumour through hole in net.
EFFECT: creation of necrosis zone in the whole volume of tumour.
SUBSTANCE: invention relates to physiotherapy and is intended for electric therapy of people Skin above focus of affection is exposed to constant current of value which does not exceed threshold of acute pain sensations, by means of electrodes applied on the body Before exposure to current, electrodes are short-circuited by regulation of variable resistor, successively connected with the source of constant current, short-circuit current is set within the range 10-60 mcA Negative electrode is applied to mouth mucosa, positive point electrode - to skin in zone of affection focus in place of the strongest pain sensation Initial current value is set within the range between the thresholds of sensations and acute pain sensations, which are determined by survey and by patient's sensor responses As acuity of patient's sensations decreases, current is gradually increased to 300-600 mcA, without exceeding threshold of acute pain sensations, and exposure to it in said point takes place during 0.5-1.5 minutes, after which, other point in zone of affection focus is influenced in similar way.
EFFECT: method allows to achieve recovery of tissue trophism in place of exposure, does not cause intensive pain sensations, adds to reduction of pain syndrome
2 cl, 6 ex
SUBSTANCE: method involves the examination of the patient with detecting pathological situations and specifying forming spastic and paretic antagonist muscles. In addition, electrical conductance of the BAP of C, F, RP, V meridians is measured by Nakatani method. The hyperfunctioning C meridian observed indicates the residual perinatal cortical hypoxias. The hyperfunctioning F meridian shows dysfunction of brain stem structures. The hypo- or hyperfunctioning RP meridian is an evidence of cerebrospinal fluid circulation disturbance. The hypo- or hyperfunctioning V meridian enables to observe decreased liquor absorption. A central pathogenesis link is involved by exposing on such BAPs of classical meridians as lo-points, associate points, tonic points and joint points. Such scalp regions as an initiative zone, an active thinking zone or a motional consequence zone are covered additionally. The BAPs exposure both on the central pathogenesis link, and on the peripheral neuromuscular apparatus is enabled by direct negative polarity current in a sedative exposure mode, and/or by direct alternated polarity current pulses in a toning exposure mode. The peripheral neuromuscular apparatus is covered by sedative exposure on spastic muscle and toning exposure - on paretic muscles, and also by sedative exposure on paravertebral BAPs considering the segmental innervation of spastic muscles.
EFFECT: method improves clinical effectiveness in ICP ensured by maintained combination of reflex and direct exposure on muscular fibres of spastic and paretic antagonist muscles, decreased stretch reflex and relief of pathological situations, clinical efficiency in ICP for the patients with the evident manifestations of hydrocephaly and organic cerebral damage caused by medical exposure on individual combinations of pathogenesis elements.
7 cl, 3 ex
SUBSTANCE: invention refers to restorative medicine, cardiology, and physiotherapy. Thorax is exposed to intratissular electrophoresis of non-steroidal anti-inflammatory drug. Packed electrodes of the area 25 cm2 are arranged bilaterally along the mid-axillary lines. Current intensity is 15-20 mA. Duration of a procedure of 25-30 minutes. The therapeutic course includes 5-6 daily procedures.
EFFECT: method improves effectiveness of early recovery rehabilitation in patients with postoperative complications presented by pericarditis and pleuritis.
2 cl, 3 tbl, 1 ex
SUBSTANCE: electric current of one of needle electrodes is transformed to voltage and amplified in an input cascade several times. A nonlinear element is used to limit or not to limit voltage amplitude regarding its value. Voltage is supplied on an output current source that forms an output current regarding the value of input voltage; tumours are exposed to this current through the other needle electrode. A device for treating tumours comprises at least a pair of needle electrodes. The input cascade of the device is connected to one of needle electrodes for current deflection therefrom, current transformation to voltage, severalfold voltage amplification and maintenance of required input resistance of the whole device. The nonlinear element is connected to an output of the input cascade and required to change current loop gain regarding the level of an input signal. The output of the nonlinear element is connected to a output current source required to generate output current. The output of the current source is connected to the other needle electrode required to introduce output current into the tumour.
EFFECT: inventions allow for creation of a positive feedback between the input cascade and the output current source.
2 cl, 1 ex, 2 dwg
SUBSTANCE: invention refers to medical equipment, namely a pushbutton assembly to be applied in an injection device, specifically to such assembly wherein the pushbutton rotates about a couple drive member. The pushbutton assembly for the injection device comprises a pushbutton mounted on the drive member which is rotatable about the pushbutton. The pushbutton is provided with a canal with a surface forming a bottom covering a flange on the drive element. The flange has an upper surface. The surface forming the canal bottom, and said upper surface form a rotary support. According to the other version of implementation, the pushbutton for the injection device has a canal for inserting the device arranged along the central axis, formed with a support arranged in the centre in the surface representing the canal bottom.
EFFECT: invention minimises the forces to be applied by the user for dose injection.
7 cl, 2 dwg